Cancer Stem Cell Therapies: Mapping the Future Growth Potential

LONDON - April 6, 2018 - PRLog -- Roots Analysis has announced the addition of "Cancer Stem Cell Therapies Market, 2017-2030" report to its list of offerings.

Ishita Nanda, the principal analyst, stated, "The frequent failure in trying to treat advanced cancers using the current standard of care therapies has been attributed to the presence of cancer stem cells (CSC) as these cells actively resist all methods of treatment, including chemotherapy and radiotherapy. The objective of the ongoing R&D is to develop novel CSC directed treatments that can combat complications, such as off target toxicities and disease relapse."

The report examines the current landscape and the future outlook of the growing pipeline of products targeting CSCs. The study covers the following:

1.     A review of the overall landscape of the CSC therapy market with respect to the phase of development, key therapeutic targets, oncological indications, mode of administration, type of molecule, geographical distribution of R&D efforts and the key players in this domain.

2.     A detailed publication analysis on more than 340 articles that have been published between September 2016 and October 2017, highlighting the key focus areas of the ongoing research activity in this field.

3.     Comprehensive profiles of phase II, phase III and marketed drugs featuring a brief company overview and financial details, product description, mechanism of action, current status of development, active clinical trials, key clinical trial results, manufacturing information, dosage and sales information, collaborations established related to the product, and a comprehensive future outlook of the developer.

4.     Insightful representations of the distribution of CSC targeting molecules across various parameters, such as target molecular pathway, therapeutic area, type of molecule and highest phase of development.

5.     The report features a bull's eye analysis to specifically highlight the most popular targets from a clinical standpoint. In addition, we have provided a comprehensive overview (in the form of a 2 X 2 matrix) of the competitive landscape of developers, highlighting each developer's product portfolio, company size and location of headquarters.

6.     An analysis depicting the prevalent and emerging trends related to CSC therapies as observed on the social media platform, Twitter, between 2012-2017.

One of the key objectives of the report was to estimate the future size of the CSC therapy market, specifically in the US and EU. We adopted a bottom-up approach to evaluate the likely success and growth of marketed drugs and those that are in phase II and phase III of clinical development, over the next 10-15 years.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The report presents details of conversations with (in alphabetical order of company name) Stephen Franklin (CEO, Evgen Pharma), Steven Swanson (Senior Vice President, Immunocellular Therapeutics) and Jaffer Ajani (Researcher at MD Anderson Cancer Center).

For additional details, please visit

https://www.rootsanalysis.com/reports/view_document/non-invasive-cancer-diagnostics-market-2nd-edition-2017-2030/164.html

or email sales@rootsanalysis.com

Contact:

Gaurav Chaudhary

+1-604-595-4954
gaurav.chaudhary@rootsanalysis.com